Business Context and Reporting Period
This Form 8-K Current Report, dated June 1, 2017, pertains to Lion Biotechnologies, Inc. (Note: The request metadata references "IOVANCE BIOTHERAPEUTICS, INC.", but the filing text explicitly identifies the registrant as Lion Biotechnologies, Inc.). The report details the Company's reincorporation from the State of Nevada to the State of Delaware, effective June 1, 2017, and the results of its Annual Meeting of Stockholders held on the same date.
Key Financial Metrics
This filing is a current report regarding corporate governance and structural changes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial statement items.
Material Changes Versus Prior Period
- State of Incorporation: The Company changed its domicile from Nevada to Delaware. The resulting entity ("Lion-Delaware") is the same legal entity as the prior Nevada corporation ("Lion-Nevada") and retains all rights, properties, debts, and liabilities.
- Security Conversions: All outstanding common stock, Series A and Series B Preferred Stock, employee options, and warrants automatically converted into equivalent Delaware securities without action by stockholders. Trading symbol "LBIO" on the Nasdaq Global Market remained unchanged.
- Governing Law: Corporate affairs are now governed by Delaware corporation laws rather than Nevada laws.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary focus is the legal mechanics of the reincorporation and the ratification of the independent auditor (Marcum LLP). The filing notes that certain stockholder rights changed as a result of the reincorporation, with full details referenced in the Definitive Proxy Statement filed on April 20, 2017.
Important Facts for Investor Verification
- Reincorporation Approval: Stockholders approved the reincorporation (Proposal 3) with 38,642,734 "FOR" votes versus 6,190,743 "AGAINST" votes.
- Board Election: Seven directors were elected, including Maria Fardis, Wayne P. Rothbaum, and Iain Dukes, with significant "FOR" vote majorities.
- Stockholder Participation: Approximately 85.3% of outstanding shares (53,208,371 shares) were present at the Annual Meeting.
- Continuity of Operations: The reincorporation did not alter the Company's federal securities law positions, trading status, or the terms of existing equity awards and employment agreements.
- Exhibits: The Plan of Conversion, Articles of Conversion, and new Delaware Certificate of Incorporation and Bylaws are filed as Exhibits 2.1, 3.1, 3.2, 3.3, and 3.4.